US3618604A - Ocular insert - Google Patents
Ocular insert Download PDFInfo
- Publication number
- US3618604A US3618604A US831761A US3618604DA US3618604A US 3618604 A US3618604 A US 3618604A US 831761 A US831761 A US 831761A US 3618604D A US3618604D A US 3618604DA US 3618604 A US3618604 A US 3618604A
- Authority
- US
- United States
- Prior art keywords
- drug
- medication
- polymeric material
- dispensing tablet
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229940079593 drug Drugs 0.000 claims abstract description 97
- 239000003814 drug Substances 0.000 claims abstract description 97
- 239000000463 material Substances 0.000 claims abstract description 51
- 210000001508 eye Anatomy 0.000 claims abstract description 39
- 239000007788 liquid Substances 0.000 claims abstract description 22
- 210000005252 bulbus oculi Anatomy 0.000 claims abstract description 21
- 238000009792 diffusion process Methods 0.000 claims abstract description 15
- 210000000795 conjunctiva Anatomy 0.000 claims abstract description 8
- 210000003717 douglas' pouch Anatomy 0.000 claims abstract description 8
- 210000003786 sclera Anatomy 0.000 claims abstract description 8
- 238000003780 insertion Methods 0.000 claims abstract description 5
- 230000037431 insertion Effects 0.000 claims abstract description 5
- 239000007947 dispensing tablet Substances 0.000 claims description 41
- 239000000017 hydrogel Substances 0.000 claims description 13
- -1 polyethylene terephthalate Polymers 0.000 claims description 13
- 229920002379 silicone rubber Polymers 0.000 claims description 12
- 239000004945 silicone rubber Substances 0.000 claims description 12
- 239000004677 Nylon Substances 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 10
- 229920001778 nylon Polymers 0.000 claims description 10
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 9
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 9
- 229960005091 chloramphenicol Drugs 0.000 claims description 9
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 9
- 210000001519 tissue Anatomy 0.000 claims description 9
- 210000000744 eyelid Anatomy 0.000 claims description 8
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 claims description 7
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 claims description 7
- 229960001416 pilocarpine Drugs 0.000 claims description 7
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 7
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 7
- 239000013583 drug formulation Substances 0.000 claims description 6
- 239000011159 matrix material Substances 0.000 claims description 6
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 6
- 239000011118 polyvinyl acetate Substances 0.000 claims description 6
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 6
- 239000004800 polyvinyl chloride Substances 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 5
- 108010035532 Collagen Proteins 0.000 claims description 5
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 5
- 229920001436 collagen Polymers 0.000 claims description 5
- 229960003957 dexamethasone Drugs 0.000 claims description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 5
- 230000000144 pharmacologic effect Effects 0.000 claims description 5
- 229920000570 polyether Polymers 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 229920011532 unplasticized polyvinyl chloride Polymers 0.000 claims description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 230000002035 prolonged effect Effects 0.000 claims description 4
- YPJUNDFVDDCYIH-UHFFFAOYSA-M 2,2,3,3,4,4,4-heptafluorobutanoate Chemical compound [O-]C(=O)C(F)(F)C(F)(F)C(F)(F)F YPJUNDFVDDCYIH-UHFFFAOYSA-M 0.000 claims description 3
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 claims description 3
- 229920002302 Nylon 6,6 Polymers 0.000 claims description 3
- 229920012485 Plasticized Polyvinyl chloride Polymers 0.000 claims description 3
- 239000003732 agents acting on the eye Substances 0.000 claims description 3
- 230000004397 blinking Effects 0.000 claims description 3
- 229920001971 elastomer Polymers 0.000 claims description 3
- 229940023490 ophthalmic product Drugs 0.000 claims description 3
- 229960003910 promethazine Drugs 0.000 claims description 3
- 229940066528 trichloroacetate Drugs 0.000 claims description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 3
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 239000002674 ointment Substances 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
- GIKNHHRFLCDOEU-UHFFFAOYSA-N 4-(2-aminopropyl)phenol Chemical compound CC(N)CC1=CC=C(O)C=C1 GIKNHHRFLCDOEU-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 229960005475 antiinfective agent Drugs 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- QSAVEGSLJISCDF-UHFFFAOYSA-N 2-hydroxy-2-phenylacetic acid (1,2,2,6-tetramethyl-4-piperidinyl) ester Chemical compound C1C(C)(C)N(C)C(C)CC1OC(=O)C(O)C1=CC=CC=C1 QSAVEGSLJISCDF-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 208000025679 Bell phenomenon Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- UUOUOERPONYGOS-CLCRDYEYSA-N Fluocinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 UUOUOERPONYGOS-CLCRDYEYSA-N 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- ZTVIKZXZYLEVOL-MCOXGKPRSA-N Homatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(O)C1=CC=CC=C1 ZTVIKZXZYLEVOL-MCOXGKPRSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 241000446313 Lamella Species 0.000 description 1
- GZENKSODFLBBHQ-ILSZZQPISA-N Medrysone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@H](C(C)=O)CC[C@H]21 GZENKSODFLBBHQ-ILSZZQPISA-N 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- REYFJDPCWQRWAA-UHFFFAOYSA-N antazoline Chemical compound N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 REYFJDPCWQRWAA-UHFFFAOYSA-N 0.000 description 1
- 229960002469 antazoline Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940055075 anticholinesterase parasympathomimetics Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 229960002028 atropine sulfate Drugs 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- SKYSRIRYMSLOIN-UHFFFAOYSA-N cyclopentolate Chemical compound C1CCCC1(O)C(C(=O)OCCN(C)C)C1=CC=CC=C1 SKYSRIRYMSLOIN-UHFFFAOYSA-N 0.000 description 1
- 229960001815 cyclopentolate Drugs 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- YHKBUDZECQDYBR-UHFFFAOYSA-L demecarium bromide Chemical compound [Br-].[Br-].C=1C=CC([N+](C)(C)C)=CC=1OC(=O)N(C)CCCCCCCCCCN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 YHKBUDZECQDYBR-UHFFFAOYSA-L 0.000 description 1
- 229960003715 demecarium bromide Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- OVXQHPWHMXOFRD-UHFFFAOYSA-M ecothiopate iodide Chemical compound [I-].CCOP(=O)(OCC)SCC[N+](C)(C)C OVXQHPWHMXOFRD-UHFFFAOYSA-M 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229950002420 eucatropine Drugs 0.000 description 1
- 150000002193 fatty amides Chemical class 0.000 description 1
- 229940043075 fluocinolone Drugs 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960004905 gramicidin Drugs 0.000 description 1
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
- 229960000857 homatropine Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 229950005360 hydroxyamfetamine Drugs 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960001011 medrysone Drugs 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229960001869 methapyrilene Drugs 0.000 description 1
- HNJJXZKZRAWDPF-UHFFFAOYSA-N methapyrilene Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CS1 HNJJXZKZRAWDPF-UHFFFAOYSA-N 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 239000003604 miotic agent Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000002637 mydriatic agent Substances 0.000 description 1
- 230000002911 mydriatic effect Effects 0.000 description 1
- 238000002402 nanowire electron scattering Methods 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
- 229960001907 nitrofurazone Drugs 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960001190 pheniramine Drugs 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229940100008 phospholine iodide Drugs 0.000 description 1
- YXJYBPXSEKMEEJ-UHFFFAOYSA-N phosphoric acid;sulfuric acid Chemical compound OP(O)(O)=O.OS(O)(=O)=O YXJYBPXSEKMEEJ-UHFFFAOYSA-N 0.000 description 1
- HZOTZTANVBDFOF-PBCQUBLHSA-N physostigmine salicylate Chemical compound OC(=O)C1=CC=CC=C1O.C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C HZOTZTANVBDFOF-PBCQUBLHSA-N 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 229960003212 sodium propionate Drugs 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002673 sulfacetamide Drugs 0.000 description 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
- 229960000654 sulfafurazole Drugs 0.000 description 1
- 229960005158 sulfamethizole Drugs 0.000 description 1
- VACCAVUAMIDAGB-UHFFFAOYSA-N sulfamethizole Chemical compound S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000004520 water soluble gel Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
Definitions
- Drug-dispensing ocular insert is comprised of a flexible body of polymeric material that is insoluble in tear liquid and has an imperforate surface.
- the polymeric material contains a drug which is dispensed to the eye in a therapeuti cally effective amount by diffusion through the polymeric material.
- the ocular insert is adapted for insertion in the culde-sac of the conjunctiva between the sclera of the eyeball and the lower lid, to be held in place against the eyeball by the pressure of the lid.
- PATENTEUNUV 91971 3.618504 mvsmron RICHARD A. NESS BACKGROUND OF THE INVENTION This invention relates to an ocular insert for dispensing drugs to the eye over a prolonged period of time.
- U.S. Pat. No. 3,416,530 granted Dec. 17, 1968, and assigned to the assignee of this invention, is directed to my invention of a drug-dispensing ocular insert that truly acts as a depot or drug reservoir, retaining and slowly releasing drug to the eye for prolonged periods of time.
- ocular inserts are fabricated of flexible polymeric materials that are biologically inert, nonallergenic, and insoluble in tear liquid.
- the ocular insert is placed in the culde-sac of the conjunctiva between the sclera of the eyeball and the lid.
- the polymeric material from which the ocular insert is formed is insoluble in tear liquid it retains its integrity and remains intact during the course of therapy, acting as a reservoir to continuously release drug to the eye and sur rounding tissues at a rate which is not affected by dissolution or erosion of the polymeric material.
- the ocular insert is removed from the cul-de-sac.
- a single such ocular insert provides the complete ophthalmic dosage regime for a particular time period, on the order of 24 hours or longer. Frequent repeated applications, as is necessary with liquids, ointments, or watersoluble lamellae, often requiring awakening the patient during the night, are avoided.
- U.S. Pat. No. 3,416,530 describes using polymeric materials which are perforated with capillary openings. While these capillary openings are effective to release drug to the eye, they add considerable complexity to the manufacture of ocular inserts; for its is difficult to control the size of these openings in large-scale manufacturing using various polymers.
- Still another object of this invention dependent upon the size and pores in the polymeric body of the is to provide a drugdispensing ocular insert which is comfortable to wear for long resides in a drug-dispensing ocular insert periods and does not cause discomfort during sleeping and normal daily wear.
- one feature of this invention to deliver during to the eye over aprolonged period of time comprising a flexible ody of polymeric material insoluble in tear liquid and having an imperforate surface, the body containing a drugwhichis dispensed to the eye in a therapeutically effective amount by diffusion through the polymeric material.
- the ocular insert of this invention is adapted for insertion in the cul-de-sac of the conjunctiva betweenthe sclera of the eyeball and the lower lid, to be held in place against the eyeball by the pressure of the lid.
- insert is designed for placement and eyelid and is fabricated of a perforate surface, that therethrough.
- Polymeric materials used in forming the ocular insert are flexible, biologically inert, insoluble in tear liquid, and nonallergenic. It is important that thepolyrneric material be capable of transferring the drug through its unbrokenwalls by the diffusion of drug or drug solution therethrough. By utilizing the mechanism of difiusion to dispense drug to the eye, the rate of drug release can be controlled with precision and reproducibility. In each case, selection of the polymeric material is dependent on the particular drug and drug form to be used in the device.
- Exemplary materials forfabricating the ocular insert include hydrophobic polymers such as plasticized or unplasticized polyvinylchloride, plasticized nylon, unplasticized soft nylon, plasticized polyethylene terephtahalate, and silicone rubber; and hydrophilic polymers such as the hydrophilic hydrogels of esters of acrylic and methacrylic acid (as described in U.S. Pat. Nos. 2,976,576 and 3,220,960 and modified collagen, cross-linked hydrophilic polyether gels (as described in U.S. Pat. No. 3,419,006), cross-linked polyvinylalcohol, and cross-linked partially hydrolyzed polyvinylacetate.
- various plasticizers kriown to the art can be employed, such as long-chain fatty amides, higher alcohols, and dioctyl phthalate.
- hydrophilic polymers suitable for use in this invention absorb forming a hydrogel therewith. Tear liquid entering to form the swollen hydrogel molecules dissolves the drug within the polymeric body, and the resulting drug solution then diffuses outwardly from: the the hydrogel structure. Therefore, as used in this specification and the appended claims, the term diffusion? refers to the movement of a drug through an imperforate polymeric body, as well as to the movement of adrug solution through an imperforate body.
- insoluble in tear liquidf means that the polymeric materials do not dissolve and erode as a result of the action of tear liquid, but may absorb tear liquid, forming a swollen hydrogel.
- any of the drugs used to treat the eye and surrounding tissues can be incorporated in the ocular insert of this invention.
- drugs which will pass through the eye or the tissue surrounding the eye to the bloodstream, but which are not used in therapy of the eye itself can be incorporated in the ocular insert.
- Suitable drugs for use in therapy of the eye with the ocular insert include, without limitation: Anti-infectives: such as antibiotics, including tetracycline, chlortetracycleine, bacitracin, neomycin, polymyxin, gramicidin, oxytetracycline, chloramphenicol, and erythromycin; sulfonamides, including sulfacetamide, sulfamethizole, and sulfisoxazole; antivirals, including idoxuridine; and other anti-infectives including nitrofurazone and sodium propionate; Antiallergenics such as antazoline, methapyrilene, chlorpheniramine, pyrilamine and prophenpyridamine; Anti-inflammatories such as hydrocortisone, hydrocortisone acetate, dexamethasone, dexamethasone 2l-phosphate, fluocinolone, medrysone, prednisolone, pred
- Drugs can be in various forms, such as uncharged molecules, components of molecular complexes, or nonirritating, pharmacologically acceptable salts, such as hydrochloride, hydrobromide, sulfate phosphate, nitrate, borate, acetate, maleate, tartrate, salicylate, etc.
- pharmacologically acceptable salts such as hydrochloride, hydrobromide, sulfate phosphate, nitrate, borate, acetate, maleate, tartrate, salicylate, etc.
- simple derivatives of the drugs such as ethers, esters, amides, etc., which have desirable retention and release characteristics but which are easily hydrolyzed by body pH, enzymes, etc. can be employed.
- the amount of drug incorporated in the ocular insert varies widely, depending on the particular drug, the desired therapeutic effect, and the time span for which the ocular insert will be used.
- the ocular insert is intended to provide the complete dosage regime for eye therapy for but a particular time span, such as 24 hours, there is no critical upper limit on the amount of drug incorporated in the device. For when the device is removed and disposed of it makes little difference whether any drug remains in the device. The lower limit will depend on the activity of the drug and its capability of being released from the device. Thus it is not practical to define a range for the therapeutically effective amount of drug incorporated into the device. However, typically, from I microgram to l milligram of drug is incorporated in the ocular insert.
- the polymeric material used to form the ocular insert is chosen for its compatibility with a particular drug and its capability of releasing that drug by diffusion at an appropriate rate over a prolonged period of time.
- Specific, but nonlimiting, examples of combinations of drugs and polymers for use in forming the ocular insert are: (l) chloramphenicol incorporated into polyethylene terephthalate plasticized with higher alcohols; (2) promethazine trichloroacetate incorporated into polyvinylchloride plasticized with dioctylphthalate; (3) chloramphenicol dispersed throughout polydimethylsiloxane rubber; (4) pilocarpine or pilocarpine perfluorobutyrate incorporated into polyvinylchloride plasticized with dioctylsebecate; and (5) dexamethasone incorporated into nylon-plasticized with higher alcohols.
- the ocular insert can be fabricated in any convenient shape for comfortable retention in the cul-de-sac. It is important, however, that the device have no sharp, jagged, or rough edges which can irritate the sensitive tissues of the eye.
- the marginal outline of the ocular insert can be ellipsoid, beanshaped, rectangular, etc. In cross section, in can be concavoconvex, rectangular, etc.
- the ocular insert is flexible and, in used, will assume essentially the configuration of the scleral curvature, the original shape of the device is not of controlling importance. Dimensions of the device can vary widely.
- the lower limit on the size of the device is governed by the amount of the particular drug to be applied to the eye and surrounding tissues to elicit the desired pharmacologic response, as well as by the smallest sized device which conveniently can be inserted and removed from the eye.
- the upper limit on the size of the device is governed by the limited space within the culde-sac that conveniently and comfortably can be filled with an ocular insert.
- the ocular insert is 4 to 20 millimeters in length, l to 12 millimeters in width, and 0.1 to l millimeter in thickness.
- it is ellipsoidal in shape and about 6 X4 0.5 millimeters in size.
- the ocular insert can be a polymeric matrix with the drug dispersed therethrough or can be a sealed container with walls of polymeric material and having the drug in an interior chamber thereof.
- One such container has a circular or ellipsoidal cross section and is tapered at the ends.
- Drug can be incorporated in the ocular insert in many ways. When the ocular insert is in the form of a container, any of the encapsulation, bonding, and coating techniques conventionally used in the art can be employed.
- the ocular insert When the ocular insert is a solid matrix with the drug dispersed therethrough, it can be fabricated by adding the drugs to the monomers prior to polymerization; adding the drug to the polymer in liquid form, molding and curing; or by impregnating the polymeric material, either before or after shaping to the form of the ocular insert, with the drug.
- the ocular insert 10 (shown by dot and dash lines in FIG. 1), it is placed in the cul-de-sac ll of the conjunctiva 12 between sclera 13 of the eyeball l4 and the lower lid 15.
- the pressure of the lower lid 15 maintains the ocular insert 10 in place.
- the ocular insert 10 With the ocular insert 10 under the lower lid 15, the device is comfortable to the wearer and does not contact the cornea 16 during sleeping nor during normal ocular motion.
- the ocular insert 10 functions as a drug reservoir gradually releasing drug to the eye and surrounding tissue. Drug 17 leaving the ocular insert by diffusion is transported to the eyeball 14 by the flow of tear liquid and by the blinking action of the eyelids.
- the eye is continuously bathed with drug 17 over a particular time span. Normally, the ocular insert 10 will be retained in place for a period of 24 hours, thereby supplying the complete dosage regime for eye therapy over that period of time.
- the polymeric body 18 of the ocular insert does not dissolve or erode in tear liquid and a predictable and reproducible dosage regime is provided.
- liquid polydimethylsiloxane (dow Corning Silastic 382) is mixed with chloramphenicol antibiotic.
- stannous octoate catalyst 0.5 percent by weight is added to the mixture is poured into a mold having an ellipsoidal cavity 6 millimeters by 4 millimeters by 0.5 millimeter to cure the silicone rubber at room temperature.
- the resulting ocular insert formed of silicone rubber contains 0.5 milligram of chloramphenicol.
- the ocular insert When inserted in the cul-de-sac of the conjunctiva between the sclera of the eyeball and the lower lid, the ocular insert is effective to deliver to the eye the dose of chloramphenicol antibiotic required for 24 hours of treatment of infection. After that period of time, the ocular insert, with its dimensions unchanged, is removed from the cul-desac and an identical insert placed in its stead to continue the therapeutic program for an additional 24 -hour period.
- the improved ocular insert of this invention offers many advantages. As it is formed of a polymeric material, insoluble in tear liquid, the ocular insert does not dissolve or erode in tear liquid during the course of therapeutic program. This permits the therapeutic program to be precisely controlled and the release of drug predicted with accuracy. That the ocular insert releases drug by diffusion is most important, since this too provides for close control over the rate of drug release from the polymer.
- a medication-dispensing tablet for a human eyeball comprising a reservoir of drug formulation confined within a flexible, imperforate and continuous-surfaced body of nonallergenic polymeric material which is insoluble in tear liquid, said body being formed of a drug-release rate-controlling polymer to continuously meter the flow of drug by diffusion from the reservoir to the eye at a controlled, predetermined and reproducible rate over a prolonged period of time, said body being adapted for insertion into the cul-de-sac of the conjunctiva between the sclera of the eyeball and eyelid, to be held in place against the eyeball by the pressure of the lid, and said body having a marginal outline and cross section adapted to assume essentially the configuration of the scleral curvature; said drug being capable of transport through the unbroken walls of said body by diffusion and said body being so constructed and arranged that, when applied to the eyeball, to dispense said drug leaving said body by diffusion is transported to the eyeball by the flow of tears and by
- polymeric material is selected from the group consisting of plasticized or unplasticized polyvinyl chloride, plasticized nylon, unplasticized soft nylon, plasticized polyethylene terephthalate, silicone rubber, hydrophilic hydrogel of an ester of acrylic or methacrylic acid, modified collagen, cross-linked hydrophilic polyether gel, cross-linked polyvinyl alcohol, and cross-linked partially hydrolyzed polyvinyl acetate.
- polymeric material is selected from the group consisting of plasticized unplasticized polyvinyl chloride, plasticized nylon, unplasticized soft nylon, plasticized polyethylene terephthalate, silicone rubber, hydrophilic hydrogel of an ester of acrylic or methacrylic acid, modified collagen, cross-linked hydrophilic polyether gel, cross-linked polyvinyl acetate.
- the medication-dispensing tablet as defined by claim I wherein same ranges from 4 to 20 millimeters in length, l to 12 millimeters in width, and 0.1 to l millimeter in thickness.
- Claim 7, line 2 insert or between “plasticized” and “unplasticized”. Claim 7, line 7, after "polyvinyl delete “acetate.” and insert alcohol, and cross-linked partially hydrolyzed polyvinyl acetate.--. Claim 20, line 47, "perfluorbutyrate” should read perfluorobutyrate.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Ophthalmology & Optometry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
Abstract
Drug-dispensing ocular insert is comprised of a flexible body of polymeric material that is insoluble in tear liquid and has an imperforate surface. The polymeric material contains a drug which is dispensed to the eye in a therapeutically effective amount by diffusion through the polymeric material. The ocular insert is adapted for insertion in the cul-de-sac of the conjunctiva between the sclera of the eyeball and the lower lid, to be held in place against the eyeball by the pressure of the lid.
Description
United States Patent Inventor Richard A. Ness Fergus Falls, Minn. App]. No. 831,761 Filed June 9, 1969 Patented Nov. 9, 1971 Assignee Alza Corporation OCULAR INSERT 21 Claims, 2 Drawing Figs. US. Cl. 128/260, 128/156 lnt .Cl ..A6lm 31/00 Field 01 Search 128/260, 296, 156
[56] References Cited UNITED STATES PATENTS 3,220,960 1 1/ 1965 Wichterle 260/25 3,339,546 9/1967, Chen 128/156 3,416,530 12/1968 Ness 128/260 Primary Examiner-Robert W. Michell Assistant ExaminerR. P. Dyer Attorney-Steven D. Goldby ABSTRACT: Drug-dispensing ocular insert is comprised of a flexible body of polymeric material that is insoluble in tear liquid and has an imperforate surface. The polymeric material contains a drug which is dispensed to the eye in a therapeuti cally effective amount by diffusion through the polymeric material. The ocular insert is adapted for insertion in the culde-sac of the conjunctiva between the sclera of the eyeball and the lower lid, to be held in place against the eyeball by the pressure of the lid.
PATENTEUNUV 91971 3.618504 mvsmron RICHARD A. NESS BACKGROUND OF THE INVENTION This invention relates to an ocular insert for dispensing drugs to the eye over a prolonged period of time.
At the present time, diseases of the eye are treated by applying ophtahalmic drugs in liquid or ointment form. To be effective in many cases, the application of drug should be substantially continuous. Such continuous delivery of drug is not obtained through the use of liquid or ointment dosage forms, even though they be applied at intervals during the day and night. Periodic application of these dosage forms results in the eye receiving a massive, but unpredictable, amount of drug at the time of application but the drug is washed away rapidly by tears, leaving the eye without medication until the nextapplication. Ointment dosage forms are presently available only in unsterilized form and this too presents a problem.
At a very early time, drugs were dissolved or'dispersed in a water-soluble gel of gylcerinated gelatin that was shaped to the form of a lamella or eye disk. These lamellae were applied to the inner surface of the eyelid to supply drug to the eye. In use, the glycerinated gelatin vehicle liquid, producing the fonns. Lamellae were same type of effect as liquid dosage not a sustained-release dosage form. To my knowledge, they are not used in this country, although they may be' used to a small extent in Europe. Further information on these water-soluble dosage forms can be found in Remingtons Pharmaceutical Sciences, Xlll, pages 547-8 (Mack Publishing Co., Easton, Pa. 1965); Fishbum, An Introduction to Pharmaceutical Formulation, page 116 (Pergamon Press Ltd, New York Cit NY. 1965); and U.S. Pat. No. 273,410,Mar.6, 1883.
U.S. Pat. No. 3,416,530, granted Dec. 17, 1968, and assigned to the assignee of this invention, is directed to my invention of a drug-dispensing ocular insert that truly acts as a depot or drug reservoir, retaining and slowly releasing drug to the eye for prolonged periods of time. Such ocular inserts are fabricated of flexible polymeric materials that are biologically inert, nonallergenic, and insoluble in tear liquid. To initiate the therapeutic program, the ocular insert is placed in the culde-sac of the conjunctiva between the sclera of the eyeball and the lid. Since the polymeric material from which the ocular insert is formed is insoluble in tear liquid it retains its integrity and remains intact during the course of therapy, acting as a reservoir to continuously release drug to the eye and sur rounding tissues at a rate which is not affected by dissolution or erosion of the polymeric material. On termination of the therapeutic program, the ocular insert is removed from the cul-de-sac. Thus, a single such ocular insert provides the complete ophthalmic dosage regime for a particular time period, on the order of 24 hours or longer. Frequent repeated applications, as is necessary with liquids, ointments, or watersoluble lamellae, often requiring awakening the patient during the night, are avoided.
To provide for release of ophthalmic drug from the polymeric body of the ocular insert, U.S. Pat. No. 3,416,530 describes using polymeric materials which are perforated with capillary openings. While these capillary openings are effective to release drug to the eye, they add considerable complexity to the manufacture of ocular inserts; for its is difficult to control the size of these openings in large-scale manufacturing using various polymers.
The best mode contemplated for practicing the invention of U.S. Pat. 3,416,530, was, at the time the patent application maturing to that patent was filed, to place the ocular insert under the upper eyelid in generally radically spaced relation to the cornea of the eyeball and in the path of flow of tears from the associated lachrymal gland. However, the eye has a tendency to roll upwardly during sleeping a process known as Bell's Phenomenon, which may cause discomfort to some persons if the ocular insert is under the upper lid.
dissolved'rapidly in tear 2 SUMMARY OF THE INVENTION dispensing ocular insert which delivers drugs to the eye at a controlled rate, that is not number of perforations or ocular insert. 7
Still another object of this invention dependent upon the size and pores in the polymeric body of the is to provide a drugdispensing ocular insert which is comfortable to wear for long resides in a drug-dispensing ocular insert periods and does not cause discomfort during sleeping and normal daily wear. In accomplishing these objects, one feature of this invention to deliver during to the eye over aprolonged period of time, comprising a flexible ody of polymeric material insoluble in tear liquid and having an imperforate surface, the body containing a drugwhichis dispensed to the eye in a therapeutically effective amount by diffusion through the polymeric material. The ocular insert of this invention is adapted for insertion in the cul-de-sac of the conjunctiva betweenthe sclera of the eyeball and the lower lid, to be held in place against the eyeball by the pressure of the lid.
Other objects features and advantages of the invention will become more apparent from the following description of the invention and from the claims.
.Belgian Pat. No. 701,813),
DETAILED DESCRlPTlON or THE INVENTION In accordance with this invention, insert is designed for placement and eyelid and is fabricated of a perforate surface, that therethrough.
Polymeric materials used in forming the ocular insert are flexible, biologically inert, insoluble in tear liquid, and nonallergenic. It is important that thepolyrneric material be capable of transferring the drug through its unbrokenwalls by the diffusion of drug or drug solution therethrough. By utilizing the mechanism of difiusion to dispense drug to the eye, the rate of drug release can be controlled with precision and reproducibility. In each case, selection of the polymeric material is dependent on the particular drug and drug form to be used in the device. Exemplary materials forfabricating the ocular insert include hydrophobic polymers such as plasticized or unplasticized polyvinylchloride, plasticized nylon, unplasticized soft nylon, plasticized polyethylene terephtahalate, and silicone rubber; and hydrophilic polymers such as the hydrophilic hydrogels of esters of acrylic and methacrylic acid (as described in U.S. Pat. Nos. 2,976,576 and 3,220,960 and modified collagen, cross-linked hydrophilic polyether gels (as described in U.S. Pat. No. 3,419,006), cross-linked polyvinylalcohol, and cross-linked partially hydrolyzed polyvinylacetate. When plasticizers are used to impart flexibility to the polymer, various plasticizers kriown to the art can be employed, such as long-chain fatty amides, higher alcohols, and dioctyl phthalate.
Those skilled in the art will appreciate that many of the hydrophilic polymers suitable for use in this invention absorb forming a hydrogel therewith. Tear liquid entering to form the swollen hydrogel molecules dissolves the drug within the polymeric body, and the resulting drug solution then diffuses outwardly from: the the hydrogel structure. Therefore, as used in this specification and the appended claims, the term diffusion? refers to the movement of a drug through an imperforate polymeric body, as well as to the movement of adrug solution through an imperforate body. Use of the expression insoluble in tear liquidf to refer to suitable polymeric materials, means that the polymeric materials do not dissolve and erode as a result of the action of tear liquid, but may absorb tear liquid, forming a swollen hydrogel.
a drug-dispensing ocular retention under the lower polymeric material, having an imwill release drug by diffusion Any of the drugs used to treat the eye and surrounding tissues can be incorporated in the ocular insert of this invention. Also, it is practical to use the eye and surrounding tissues as a point of entry for systemic drugs that enter circulation in the blood stream and produce a phannacologic response at a site remote from the point of application of the ocular insert. Thus, drugs which will pass through the eye or the tissue surrounding the eye to the bloodstream, but which are not used in therapy of the eye itself, can be incorporated in the ocular insert.
Suitable drugs for use in therapy of the eye with the ocular insert include, without limitation: Anti-infectives: such as antibiotics, including tetracycline, chlortetracycleine, bacitracin, neomycin, polymyxin, gramicidin, oxytetracycline, chloramphenicol, and erythromycin; sulfonamides, including sulfacetamide, sulfamethizole, and sulfisoxazole; antivirals, including idoxuridine; and other anti-infectives including nitrofurazone and sodium propionate; Antiallergenics such as antazoline, methapyrilene, chlorpheniramine, pyrilamine and prophenpyridamine; Anti-inflammatories such as hydrocortisone, hydrocortisone acetate, dexamethasone, dexamethasone 2l-phosphate, fluocinolone, medrysone, prednisolone, prednisolone ZI-phosphate and prednisolone acetate; Decongestants such as phenylephrine, naphazoline, and tetrahydrazoline; Miotics and anticholinesterases such as pilocarpine, eserine salicylate, carbachol, diisopropyl flur'ophosphate, phospholine iodide, and demecarium bromide; Mydriatics such as atropine sulfate, cyclopentolate, homatropine, scopolamine, tropicamide, eucatropine, and hydroxyamphetamine and Sypathomimetics such as epinephrine. Drugs can be in various forms, such as uncharged molecules, components of molecular complexes, or nonirritating, pharmacologically acceptable salts, such as hydrochloride, hydrobromide, sulfate phosphate, nitrate, borate, acetate, maleate, tartrate, salicylate, etc. Furthermore, simple derivatives of the drugs (such as ethers, esters, amides, etc.,) which have desirable retention and release characteristics but which are easily hydrolyzed by body pH, enzymes, etc. can be employed. The amount of drug incorporated in the ocular insert varies widely, depending on the particular drug, the desired therapeutic effect, and the time span for which the ocular insert will be used. Since the ocular insert is intended to provide the complete dosage regime for eye therapy for but a particular time span, such as 24 hours, there is no critical upper limit on the amount of drug incorporated in the device. For when the device is removed and disposed of it makes little difference whether any drug remains in the device. The lower limit will depend on the activity of the drug and its capability of being released from the device. Thus it is not practical to define a range for the therapeutically effective amount of drug incorporated into the device. However, typically, from I microgram to l milligram of drug is incorporated in the ocular insert.
In each case, the polymeric material used to form the ocular insert is chosen for its compatibility with a particular drug and its capability of releasing that drug by diffusion at an appropriate rate over a prolonged period of time. Specific, but nonlimiting, examples of combinations of drugs and polymers for use in forming the ocular insert are: (l) chloramphenicol incorporated into polyethylene terephthalate plasticized with higher alcohols; (2) promethazine trichloroacetate incorporated into polyvinylchloride plasticized with dioctylphthalate; (3) chloramphenicol dispersed throughout polydimethylsiloxane rubber; (4) pilocarpine or pilocarpine perfluorobutyrate incorporated into polyvinylchloride plasticized with dioctylsebecate; and (5) dexamethasone incorporated into nylon-plasticized with higher alcohols.
The ocular insert can be fabricated in any convenient shape for comfortable retention in the cul-de-sac. It is important, however, that the device have no sharp, jagged, or rough edges which can irritate the sensitive tissues of the eye. Thus the marginal outline of the ocular insert can be ellipsoid, beanshaped, rectangular, etc. In cross section, in can be concavoconvex, rectangular, etc. As the ocular insert is flexible and, in used, will assume essentially the configuration of the scleral curvature, the original shape of the device is not of controlling importance. Dimensions of the device can vary widely. The lower limit on the size of the device is governed by the amount of the particular drug to be applied to the eye and surrounding tissues to elicit the desired pharmacologic response, as well as by the smallest sized device which conveniently can be inserted and removed from the eye. The upper limit on the size of the device is governed by the limited space within the culde-sac that conveniently and comfortably can be filled with an ocular insert. Typically, the ocular insert is 4 to 20 millimeters in length, l to 12 millimeters in width, and 0.1 to l millimeter in thickness. Preferably it is ellipsoidal in shape and about 6 X4 0.5 millimeters in size.
The ocular insert can be a polymeric matrix with the drug dispersed therethrough or can be a sealed container with walls of polymeric material and having the drug in an interior chamber thereof. One such container has a circular or ellipsoidal cross section and is tapered at the ends. Drug can be incorporated in the ocular insert in many ways. When the ocular insert is in the form of a container, any of the encapsulation, bonding, and coating techniques conventionally used in the art can be employed. When the ocular insert is a solid matrix with the drug dispersed therethrough, it can be fabricated by adding the drugs to the monomers prior to polymerization; adding the drug to the polymer in liquid form, molding and curing; or by impregnating the polymeric material, either before or after shaping to the form of the ocular insert, with the drug.
Referring particularly to FIG. 1 and 2, to use the ocular insert 10 (shown by dot and dash lines in FIG. 1), it is placed in the cul-de-sac ll of the conjunctiva 12 between sclera 13 of the eyeball l4 and the lower lid 15. The pressure of the lower lid 15 maintains the ocular insert 10 in place. With the ocular insert 10 under the lower lid 15, the device is comfortable to the wearer and does not contact the cornea 16 during sleeping nor during normal ocular motion. Once in place, the ocular insert 10 functions as a drug reservoir gradually releasing drug to the eye and surrounding tissue. Drug 17 leaving the ocular insert by diffusion is transported to the eyeball 14 by the flow of tear liquid and by the blinking action of the eyelids. By use of the ocular insert, the eye is continuously bathed with drug 17 over a particular time span. Normally, the ocular insert 10 will be retained in place for a period of 24 hours, thereby supplying the complete dosage regime for eye therapy over that period of time. During the course of use, the polymeric body 18 of the ocular insert does not dissolve or erode in tear liquid and a predictable and reproducible dosage regime is provided.
In a specific example of the manufacture of an ocular insert the invention, liquid polydimethylsiloxane (dow Corning Silastic 382) is mixed with chloramphenicol antibiotic. After uniformly mixing the antibiotic with the unvulcanized silicone rubber, stannous octoate catalyst (0.5 percent by weight) is added to the mixture is poured into a mold having an ellipsoidal cavity 6 millimeters by 4 millimeters by 0.5 millimeter to cure the silicone rubber at room temperature. The resulting ocular insert formed of silicone rubber contains 0.5 milligram of chloramphenicol. When inserted in the cul-de-sac of the conjunctiva between the sclera of the eyeball and the lower lid, the ocular insert is effective to deliver to the eye the dose of chloramphenicol antibiotic required for 24 hours of treatment of infection. After that period of time, the ocular insert, with its dimensions unchanged, is removed from the cul-desac and an identical insert placed in its stead to continue the therapeutic program for an additional 24 -hour period.
Thus, the improved ocular insert of this invention offers many advantages. As it is formed of a polymeric material, insoluble in tear liquid, the ocular insert does not dissolve or erode in tear liquid during the course of therapeutic program. This permits the therapeutic program to be precisely controlled and the release of drug predicted with accuracy. That the ocular insert releases drug by diffusion is most important, since this too provides for close control over the rate of drug release from the polymer.
While there have been described and pointed out the fundamental novel features of the invention as applied to the preferred embodiment, those skilled in the art will appreciate that various modifications, changes, and omissions in the ocular insert illustrated and described can be made without departing from the spirit of the invention. It is the intention, therefore, to be limited only by the scope of the following claims.
What is claimed is:
l. A medication-dispensing tablet for a human eyeball, said tablet comprising a reservoir of drug formulation confined within a flexible, imperforate and continuous-surfaced body of nonallergenic polymeric material which is insoluble in tear liquid, said body being formed of a drug-release rate-controlling polymer to continuously meter the flow of drug by diffusion from the reservoir to the eye at a controlled, predetermined and reproducible rate over a prolonged period of time, said body being adapted for insertion into the cul-de-sac of the conjunctiva between the sclera of the eyeball and eyelid, to be held in place against the eyeball by the pressure of the lid, and said body having a marginal outline and cross section adapted to assume essentially the configuration of the scleral curvature; said drug being capable of transport through the unbroken walls of said body by diffusion and said body being so constructed and arranged that, when applied to the eyeball, to dispense said drug leaving said body by diffusion is transported to the eyeball by the flow of tears and by the blinking action of the eyelids.
2. The medication-dispensing tablet as defined by claim 1, wherein the reservoir of drug formulation is comprised of a sealed container with walls of said polymeric material and said drug is contained in an interior chamber thereof.
3. The medication-dispensing tablet as defined by claim 2, wherein said polymeric material is selected from the group consisting of plasticized or unplasticized polyvinyl chloride, plasticized nylon, unplasticized soft nylon, plasticized polyethylene terephthalate, silicone rubber, hydrophilic hydrogel of an ester of acrylic or methacrylic acid, modified collagen, cross-linked hydrophilic polyether gel, cross-linked polyvinyl alcohol, and cross-linked partially hydrolyzed polyvinyl acetate.
4. The medication-dispensing tablet as defined by claim 3, wherein said polymeric material is silicone rubber.
5. The medication-dispensing tablet as defined by claim 3, wherein said polymeric material is a hydrophilic hydrogel of an ester of acrylic or methacrylic acid.
6. The medication-dispensing tablet as defined by claim 1, wherein the reservoir of drug formulation is comprised of a matrix of the drug-release ratecontrolling polymeric material, said matrix having the drug distributed therethrough.
7. The medication-dispensing tablet as defined by claim 1,
wherein said polymeric material is selected from the group consisting of plasticized unplasticized polyvinyl chloride, plasticized nylon, unplasticized soft nylon, plasticized polyethylene terephthalate, silicone rubber, hydrophilic hydrogel of an ester of acrylic or methacrylic acid, modified collagen, cross-linked hydrophilic polyether gel, cross-linked polyvinyl acetate.
8. The medication-dispensing tablet as defined by claim 7, wherein said polymeric material is silicone rubber.
9. The medication-dispensing tablet as defined by claim 7, wherein said polymeric material is a hydrophilic hydrogel of an ester of acrylic or methacrylic acid.
10. The medication-dispensing tablet as defined by claim 1, wherein said drug is an ophthalmic drug.
11. The medication-dispensing tablet as defined by claim 1, wherein said drug is a systemically active drug which will pass through the eye to the bloodstream and produce a pharmacologic response at a site remote from the eye.
vl2. The medication-dispensing tablet as defined by claim 1, wherein said drug is a systemically active drug which will pass through the tissue surrounding the eye to the bloodstream and produce a pharmacologic response at a site remote from the l3. The medication-dispensing tablet as defined by claim 1, wherein from 1 microgram to l milligram of drug is incorporated in said tablet.
14. The medication-dispensing tablet as defined by claim 1,
I wherein same is circular in cross section and tapered at its ends.
15. The medication-dispensing tablet as defined by claim 1, wherein same is ellipsoidal in cross section and tapered at its ends.
16. The medication-dispensing tablet as defined by claim I, wherein same ranges from 4 to 20 millimeters in length, l to 12 millimeters in width, and 0.1 to l millimeter in thickness.
17. The medication-dispensing tablet as defined by claim 1, wherein the drug is chloramphenicol and the polymeric material is polyethylene terephthalate.
18. The medication-dispensing tablet as defined by claim 1, wherein the drug is promethazine trichloroacetate and the polymeric material is polyvinyl chloride.
19 The medication-dispensing tablet as defined by claim 1, wherein the drug is ehloramphenicol and the polymeric material is polydimethylsiloxane rubber.
20. The medication-dispening tablet as defined by claim 1, wherein the drug is a member selected from the group consisting of pilocarpine and pilocarpine perfiuorbutyrate and the polymeric material is polyvinyl chloride.
21. The medication-dispensing tablet as defined by claim 1, wherein the drug is dexamethasone and the polymeric material is nylon-66.
K i t i UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION Patent No. 3 8, 0 Dated November 9, 1971 Inventor(s) Richard A. Ness It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:
Column 1, line 8, "ophtahalmic" should read ophthalmic-; line 20, "gylcerinated" should read -glycerinated-; line 64, "its" should read it--; line 70, "radically" should read -radially-. Column 2, line 16, "during" should read drug-; line 50, "terephtahalate" should read terephthalate.
Column 3, line 13, "chlortetracycleine" should read --chlortetracycline; line 31, "Sypathomimetics" should read Sympathomimetics-; line 35, following the word "sulfate" insert a comma; line 69, "nylon-plasticized" should read nylon-66 plasticized-; line 75, "in", second occurrence,
should read -it-. Column 4, line 2, "used" should read use-; line 31, "FIG." should read -FIGS.-; line 50, after "insert" add of-; line 51, "dow" should read Dow--; line 55, "to" should read and. Claim 1, line 12, delete the hyphen between "continuous" and "surfaced". Claim 1, line 27, insert thereto, drug-- between "drug" and "leaving".
Claim 7, line 2, insert or between "plasticized" and "unplasticized". Claim 7, line 7, after "polyvinyl delete "acetate." and insert alcohol, and cross-linked partially hydrolyzed polyvinyl acetate.--. Claim 20, line 47, "perfluorbutyrate" should read perfluorobutyrate.
In all the claims, each occurrence, delete the hyphen between "medication" and "dispensing".
Signed and sealed this 2nd day of May 1972.
EM F'O-1050 (10-69) (SEAL) Attest:
EDWARD M.FLE'I'CHER, JR. 5055111 Li-U'l'l'SUtiJ-LLK Attesting Officer Co missioner of Patents USCOMM-DC 6O376-F69 U S GOVERNMENT PRINHNG OFFICE 1969 0-366-334
Claims (20)
1. A medication-dispensing tablet for a human eyeball, said tablet comprising a reservoir of drug formulation confined within a flexible, imperforate and continuous-surfaced body of nonallergenic polymeric material which is insoluble in tear liquid, said body being formed of a drug-release rate-controlling polymer to continuously meter the flow of drug by diffusion from the reservoir to the eye at a controlled, predetermined and reproducible rate over a prolonged period of time, said body being adapted for insertion into the cul-de-sac of the conjunctiva between the sclera of the eyeball and eyelid, to be held in place against the eyeball by the pressure of the lid, and said body having a marginal outline and cross section adapted to assume essentially the configuration of the scleral curvature; said drug being capable of transport through the unbroken walls of said body by diffusion and said body being so constructed and arranged that, when applied to the eyeball, to dispense said drug thereto, drug leaving said body by diffusion is transported to the eyeball by the flow of tears and by the blinking action of the eyelids.
2. The medication-dispensing tablet as defined by claim 1, wherein the reservoir of drug formulation is comprised of a sealed container with walls of said polymeric material and said drug is contained in an interior chamber thereof.
3. The medication-dispensing tablet as defined by claim 2, wherein said polymeric material is selected from the group consisting of plasticized or unplasticized polyvinyl chloride, plasticized nylon, unplasticized soft nylon, plasticized polyethylene terephthalate, silicone rubber, hydrophilic hydrogel of an ester of acrylic or methacrylic acid, modified collagen, cross-linked hydrophilic polyether gel, cross-linked polyvinyl alcohol, and cross-linked partially hydrolyzed polyvinyl acetate.
4. The medication-dispensing tablet as defined by claim 3, wherein said polymeric material is silicone rubber.
5. The medication-dispensing tablet as defined by claim 3, wherein said polymeric material is a hydrophilic hydrogel of an ester of acrylic or methacrylic acid.
6. The medication-dispensing tablet as defined by claim 1, wherein the reservoir of drug formulation is comprised of a matrix of the drug-release rate-controlling polymeric material, said matrix having the drug distributed therethrough.
7. The medication-dispensing tablet as defined by claim 1, wherein said polymeric material is selected from the group consisting of plasticized unplasticized polyvinyl chloride, plasticized nylon, unplasticized soft nylon, plasticized polyethylene terephthalate, silicone rubber, hydrophilic hydrogel of an ester of acrylic or methacrylic acid, modified collagen, cross-linked hydrophilic polyether gel, cross-linked polyvinyl alcohol, and cross-linked partially hydrolyzed polyvinyl acetate.
8. The medication-dispensing tablet as defined by claim 7, wherein said polymeric material is silicone rubber.
9. The medication-dispensing tablet as defined by claim 7, wherein said polymeric material is a hydrophilic hydrogel of an ester of acrylic or methacrylic acid.
10. The medication-dispensing tablet as defined by claim 1, wherein said drug is an ophthalmic drug.
11. The medication-dispensing tablet as defined by claim 1, wherein said drug is a systemically active drug which will pass through the eye to the bloodstream and produce a pharmacologic response at a site remote from the eye.
12. The medication-dispensing tablet as defined by claim 1, wherein said drug is a systemically active drug which will pass through the tissue surrounding the eye to the bloodstream and produce a pharmacologic response at a site remote from the eye.
13. The medication-dispensing tablet as defined by claim 1, wherein from 1 microgram to 1 milligram of drug is incorporated in said tablet.
14. The medication-dispensing tablet as defined by claim 1, wherein same is circular in cross section and tapered at its ends.
15. The medication-dispensing tablet as defined by claim 1, wherein same is ellipsoidal in cross section and tapered at its ends.
16. The medication-dispensing tablet as defined by claim 1, wherein same ranges from 4 to 20 millimeters in length, 1 to 12 millimeters in width, and 0.1 to 1 millimeter in thickness.
17. The medication-dispensing tablet as defined by claim 1, wherein the drug is chloramphenicol and the polymeric material is polyethylene terephthalate.
18. The medication-dispensing tablet as defined by claim 1, wherein the drug is promethazine trichloroacetate and the polymeric material is polyvinyl chloride. 19 The medication-dispensing tablet as defined by claim 1, wherein the drug is chloramphenicol and the polymeric material is polydimethylsiloxane rubber.
20. The medication-dispensing tablet as defined by claim 1, wherein the drug is a member selected from the group consisting of pilocarpine and pilocarpine perfluorobutyrate and the polymeric material is polyvinyl chloride.
21. The medication-dispensing tablet as defined by claim 1, wherein the drug is dexamethasone and the polymeric material is nylon-66.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83176169A | 1969-06-09 | 1969-06-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
US3618604A true US3618604A (en) | 1971-11-09 |
Family
ID=25259803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US831761A Expired - Lifetime US3618604A (en) | 1969-06-09 | 1969-06-09 | Ocular insert |
Country Status (2)
Country | Link |
---|---|
US (1) | US3618604A (en) |
BE (1) | BE771356A (en) |
Cited By (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3710796A (en) * | 1971-05-14 | 1973-01-16 | C Neefe | Corneal drug delivery method |
DE2243986A1 (en) * | 1971-09-09 | 1973-03-29 | Alza Corp | BIODEGRADABLE EYE INSERT FOR ADMINISTRATION OF A MEDICINAL PRODUCT |
US3811444A (en) * | 1972-12-27 | 1974-05-21 | Alza Corp | Bioerodible ocular device |
US3826258A (en) * | 1972-02-07 | 1974-07-30 | S Abraham | Gradual release medicine carrier |
US3828777A (en) * | 1971-11-08 | 1974-08-13 | Alza Corp | Microporous ocular device |
US3868445A (en) * | 1972-11-30 | 1975-02-25 | Pharmacia Ab | Dosage unit containing a substance showing a topical effect on the eye, and a method of preparing same |
US3870791A (en) * | 1972-04-24 | 1975-03-11 | Heskel M Haddad | Solid state ophthalmic medication delivery method |
US3914402A (en) * | 1973-06-14 | 1975-10-21 | Alza Corp | Ophthalmic dosage form, for releasing medication over time |
US3926188A (en) * | 1974-11-14 | 1975-12-16 | Alza Corp | Laminated drug dispenser |
USB520277I5 (en) * | 1971-09-09 | 1976-02-17 | ||
US3957049A (en) * | 1973-10-09 | 1976-05-18 | Neefe Charles W | Rechargeable drug delivery method |
US3960150A (en) * | 1971-09-09 | 1976-06-01 | Alza Corporation | Bioerodible ocular device |
US3961628A (en) * | 1974-04-10 | 1976-06-08 | Alza Corporation | Ocular drug dispensing system |
US3981303A (en) * | 1971-09-09 | 1976-09-21 | Alza Corporation | Bioerodible ocular device |
US3985897A (en) * | 1973-12-21 | 1976-10-12 | Mead Johnson & Company | Ocular hypotensive process employing dextrorotatory sulfonamidophenethanolamines |
US3986510A (en) * | 1971-09-09 | 1976-10-19 | Alza Corporation | Bioerodible ocular device |
US3993071A (en) * | 1971-09-09 | 1976-11-23 | Alza Corporation | Bioerodible ocular device |
US3993073A (en) * | 1969-04-01 | 1976-11-23 | Alza Corporation | Novel drug delivery device |
US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4014334A (en) * | 1976-02-02 | 1977-03-29 | Alza Corporation | Laminated osmotic system for dispensing beneficial agent |
US4144317A (en) * | 1975-05-30 | 1979-03-13 | Alza Corporation | Device consisting of copolymer having acetoxy groups for delivering drugs |
US4177256A (en) * | 1973-04-25 | 1979-12-04 | Alza Corporation | Osmotic bursting drug delivery device |
US4190642A (en) * | 1978-04-17 | 1980-02-26 | Alza Corporation | Ocular therapeutic system for dispensing a medication formulation |
US4281654A (en) * | 1980-04-07 | 1981-08-04 | Alza Corporation | Drug delivery system for controlled ocular therapy |
US4304226A (en) * | 1980-03-03 | 1981-12-08 | The Procter & Gamble Company | Vaginal contraceptive |
US4344431A (en) * | 1969-03-24 | 1982-08-17 | University Of Delaware | Polymeric article for dispensing drugs |
WO1984004681A1 (en) * | 1983-05-25 | 1984-12-06 | Alcon Lab Inc | Ophthalmic solution |
WO1984004680A1 (en) * | 1983-05-25 | 1984-12-06 | Alcon Lab Inc | Ophthalmic gel |
EP0212959A2 (en) * | 1985-08-16 | 1987-03-04 | BAUSCH & LOMB INCORPORATED | Sustained-release formulation containing an amin acid polymer with a lower alkyl (C1-C4) polar solvent |
EP0219208A2 (en) * | 1985-08-16 | 1987-04-22 | BAUSCH & LOMB INCORPORATED | Substained-release formulation containing an amino acid polymer |
US4660546A (en) * | 1984-11-07 | 1987-04-28 | Robert S. Herrick | Method for treating for deficiency of tears |
EP0219207A3 (en) * | 1985-08-16 | 1988-06-01 | Bausch & Lomb Incorporated | Sustained-release formulation comprising a hydrophobic polymer system |
US4959217A (en) * | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
EP0411578A1 (en) * | 1989-08-01 | 1991-02-06 | Terumo Kabushiki Kaisha | Liquid applicator |
US5185152A (en) * | 1990-01-10 | 1993-02-09 | Peyman Gholam A | Method and apparatus for controlled release drug delivery to the cornea and anterior chamber of the eye |
WO1993019707A1 (en) * | 1992-04-02 | 1993-10-14 | Bausch & Lomb Incorporated | Ophthalmic article |
US5378475A (en) * | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
US5660851A (en) * | 1989-12-26 | 1997-08-26 | Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem | Ocular inserts |
EP0863729A1 (en) * | 1995-09-27 | 1998-09-16 | Control Delivery Systems, Inc. | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
US5902598A (en) * | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
US5928662A (en) * | 1996-07-31 | 1999-07-27 | Phillips; Andrew F. | Ocular drug delivery device |
US6123957A (en) * | 1997-07-16 | 2000-09-26 | Jernberg; Gary R. | Delivery of agents and method for regeneration of periodontal tissues |
WO2000062760A1 (en) | 1999-04-19 | 2000-10-26 | Eyelab Group, Llc | Ophthalmic insert and method for sustained release of medication to the eye |
US6375972B1 (en) | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
US20020106395A1 (en) * | 2001-01-03 | 2002-08-08 | Brubaker Michael J. | Sustained release drug delivery devices with prefabricated permeable plugs |
US20020110635A1 (en) * | 2001-01-26 | 2002-08-15 | Brubaker Michael J. | Process for the production of sustained release drug delivery devices |
WO2002064071A1 (en) * | 2001-02-13 | 2002-08-22 | The Lions Eye Institute Of Western Australia | Device and method for anterior segment drug delivery |
US20020188282A1 (en) * | 2001-02-13 | 2002-12-12 | Robert Greenberg | Implantable drug delivery device |
US20020198453A1 (en) * | 2001-06-11 | 2002-12-26 | Herrick Family Limited Partnership | Implant capable of forming a differential image in an eye and methods of inserting and locating same |
US20030021828A1 (en) * | 1999-03-22 | 2003-01-30 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with substained release corticosteroids |
WO2003096876A2 (en) * | 2001-04-01 | 2003-11-27 | Sommer Phillipe L | Continuously operational diagnostic device |
US20040034357A1 (en) * | 1999-08-03 | 2004-02-19 | University Of Massachusetts, A Massachusetts Corporation | Controlled release implantable devices |
US6756049B2 (en) | 2000-12-29 | 2004-06-29 | Bausch & Lomb Incorporated | Sustained release drug delivery devices |
US6756058B2 (en) | 2001-01-03 | 2004-06-29 | Bausch & Lomb Incorporated | Sustained release drug delivery devices with multiple agents |
US20050027312A1 (en) * | 2001-08-10 | 2005-02-03 | Andreas Hahn | Balloon occlusion device |
US20060134176A1 (en) * | 2004-12-22 | 2006-06-22 | Bausch & Lomb Incorporated | Pharmaceutical delivery system and method of use |
US20060198892A1 (en) * | 2003-08-22 | 2006-09-07 | Ellis Jeanne Y | Polymeric systems for controlled drug therapy |
US20060270968A1 (en) * | 2003-03-21 | 2006-11-30 | Robert Greenberg | Transretinal implant and method of manufacture |
US20070112318A1 (en) * | 2003-08-26 | 2007-05-17 | Leahy Charles D | Ocular drug delivery device |
US20070190111A1 (en) * | 2001-03-15 | 2007-08-16 | Govemment Of The U.S.A, Represented By The Secretary, Department. Of Health And Human | Ocular therapeutic agent delivery devices and methods for making and using such devices |
US20080086101A1 (en) * | 2006-08-25 | 2008-04-10 | David Freilich | Ophthalmic insert |
US20080171072A1 (en) * | 2006-08-11 | 2008-07-17 | Frank Burczynski | Ocular inserts containing apomorphine |
US20090004245A1 (en) * | 2007-06-28 | 2009-01-01 | Orilla Werhner C | Use of an iris simulated layer to allow aesthetic appearance drug loaded contact lens |
US20090004244A1 (en) * | 2007-06-27 | 2009-01-01 | Orilla Werhner C | Iris design as a drug depot for zonal drug delivery by contact lens |
US20090162417A1 (en) * | 2007-12-21 | 2009-06-25 | Cook Incorporated | Drug eluting ocular conformer |
US7563255B2 (en) | 2001-05-03 | 2009-07-21 | Massachusetts Eye And Ear Infirmary | Implantable drug delivery device and use thereof |
US20100069857A1 (en) * | 2008-09-18 | 2010-03-18 | Oasis Research LLC | Ring Shaped Contoured Collagen Shield For Ophthalmic Drug Delivery |
WO2010093873A2 (en) | 2009-02-12 | 2010-08-19 | Incept, Llc | Drug delivery through hydrogel plugs |
US20100239637A1 (en) * | 2008-12-11 | 2010-09-23 | Massachusetts Institute Of Technology | Contact lens drug delivery device |
WO2011123180A1 (en) | 2010-04-03 | 2011-10-06 | Praful Doshi | Medical devices including medicaments and methods of making and using same |
US8133501B2 (en) | 2002-02-08 | 2012-03-13 | Boston Scientific Scimed, Inc. | Implantable or insertable medical devices for controlled drug delivery |
WO2012033730A2 (en) | 2010-09-08 | 2012-03-15 | Johnson & Johnson Vision Care, Inc. | Punctal plug containing drug formulation |
WO2012037330A1 (en) | 2010-09-17 | 2012-03-22 | Johnson & Johnson Vision Care, Inc. | Punctal plugs with directional release |
WO2012082486A1 (en) | 2010-12-16 | 2012-06-21 | Johnson & Johnson Vision Care, Inc. | Punctal plug with drug core retention features |
US8277830B2 (en) | 2009-01-29 | 2012-10-02 | Forsight Vision4, Inc. | Posterior segment drug delivery |
WO2012154427A1 (en) | 2011-05-06 | 2012-11-15 | Johnson & Johnson Vision Care, Inc. | Punctal plugs for controlled release of therapeutic agents |
US8486052B2 (en) | 2001-06-12 | 2013-07-16 | The Johns Hopkins University School Of Medicine | Reservoir device for intraocular drug delivery |
EP2633840A2 (en) | 2012-02-29 | 2013-09-04 | Johnson & Johnson Vision Care, Inc. | Punctal plug with energized containment array |
US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
US8685427B2 (en) | 2002-07-31 | 2014-04-01 | Boston Scientific Scimed, Inc. | Controlled drug delivery |
US8715712B2 (en) | 2011-09-14 | 2014-05-06 | Forsight Vision5, Inc. | Ocular insert apparatus and methods |
US8765166B2 (en) | 2010-05-17 | 2014-07-01 | Novaer Holdings, Inc. | Drug delivery devices for delivery of ocular therapeutic agents |
US8871241B2 (en) | 2002-05-07 | 2014-10-28 | Psivida Us, Inc. | Injectable sustained release delivery devices |
US8905963B2 (en) | 2010-08-05 | 2014-12-09 | Forsight Vision4, Inc. | Injector apparatus and method for drug delivery |
US8920826B2 (en) | 2002-07-31 | 2014-12-30 | Boston Scientific Scimed, Inc. | Medical imaging reference devices |
US9005649B2 (en) | 2009-07-14 | 2015-04-14 | Board Of Regents, The University Of Texas System | Methods for making controlled delivery devices having zero order kinetics |
WO2015071427A1 (en) | 2013-11-14 | 2015-05-21 | Eyed Pharma | Eye device |
US9102105B2 (en) | 2011-09-13 | 2015-08-11 | Vista Scientific Llc | Method for forming an ocular drug delivery device |
WO2015164563A1 (en) | 2014-04-25 | 2015-10-29 | Johnson & Johnson Vision Care, Inc. | Method and ophthalmic device with active agent release system |
US9421126B2 (en) | 2009-06-03 | 2016-08-23 | Forsight Vision5, Inc. | Anterior segment drug delivery |
US9474756B2 (en) | 2014-08-08 | 2016-10-25 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
US9492315B2 (en) | 2010-08-05 | 2016-11-15 | Forsight Vision4, Inc. | Implantable therapeutic device |
US9526654B2 (en) | 2013-03-28 | 2016-12-27 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
US9750636B2 (en) | 2012-10-26 | 2017-09-05 | Forsight Vision5, Inc. | Ophthalmic system for sustained release of drug to eye |
US9883968B2 (en) | 2011-09-16 | 2018-02-06 | Forsight Vision4, Inc. | Fluid exchange apparatus and methods |
US9968603B2 (en) | 2013-03-14 | 2018-05-15 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
WO2018119188A2 (en) | 2016-12-21 | 2018-06-28 | Johnson & Johnson Vision Care, Inc. | Extended period timer circuits for ophthalmic devices |
US10010502B2 (en) | 2015-05-19 | 2018-07-03 | Amorphex Therapeutics Llc | Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation |
US10010448B2 (en) | 2012-02-03 | 2018-07-03 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
US10098836B2 (en) | 2013-05-02 | 2018-10-16 | Retina Foundation Of The Southwest | Method for forming a molded two-layer ocular implant |
US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
US10172740B2 (en) | 2015-11-06 | 2019-01-08 | David E Freilich | Lacrimal stent |
US10258503B2 (en) | 2014-07-15 | 2019-04-16 | Forsight Vision4, Inc. | Ocular implant delivery device and method |
US10398592B2 (en) | 2011-06-28 | 2019-09-03 | Forsight Vision4, Inc. | Diagnostic methods and apparatus |
US10413506B2 (en) | 2010-04-03 | 2019-09-17 | Praful Doshi | Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia |
US10500091B2 (en) | 2014-11-10 | 2019-12-10 | Forsight Vision4, Inc. | Expandable drug delivery devices and methods of use |
US10617557B2 (en) | 2010-08-05 | 2020-04-14 | Forsight Vision4, Inc. | Combined drug delivery methods and apparatus |
US10874548B2 (en) | 2010-11-19 | 2020-12-29 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
US11224602B2 (en) | 2015-04-13 | 2022-01-18 | Forsight Vision5, Inc. | Ocular insert composition of a semi-crystalline or crystalline pharmaceutically active agent |
US11351058B2 (en) | 2017-03-17 | 2022-06-07 | W. L. Gore & Associates, Inc. | Glaucoma treatment systems and methods |
US11419759B2 (en) | 2017-11-21 | 2022-08-23 | Forsight Vision4, Inc. | Fluid exchange apparatus for expandable port delivery system and methods of use |
US11432959B2 (en) | 2015-11-20 | 2022-09-06 | Forsight Vision4, Inc. | Porous structures for extended release drug delivery devices |
US11617644B2 (en) | 2014-10-13 | 2023-04-04 | W. L. Gore & Associates, Inc. | Prosthetic valved conduit |
US11617680B2 (en) | 2016-04-05 | 2023-04-04 | Forsight Vision4, Inc. | Implantable ocular drug delivery devices |
US11678983B2 (en) | 2018-12-12 | 2023-06-20 | W. L. Gore & Associates, Inc. | Implantable component with socket |
USD1033637S1 (en) | 2022-01-24 | 2024-07-02 | Forsight Vision4, Inc. | Fluid exchange device |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3220960A (en) * | 1960-12-21 | 1965-11-30 | Wichterle Otto | Cross-linked hydrophilic polymers and articles made therefrom |
US3339546A (en) * | 1963-12-13 | 1967-09-05 | Squibb & Sons Inc | Bandage for adhering to moist surfaces |
US3416530A (en) * | 1966-03-02 | 1968-12-17 | Richard A. Ness | Eyeball medication dispensing tablet |
-
1969
- 1969-06-09 US US831761A patent/US3618604A/en not_active Expired - Lifetime
-
1971
- 1971-08-16 BE BE771356A patent/BE771356A/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3220960A (en) * | 1960-12-21 | 1965-11-30 | Wichterle Otto | Cross-linked hydrophilic polymers and articles made therefrom |
US3339546A (en) * | 1963-12-13 | 1967-09-05 | Squibb & Sons Inc | Bandage for adhering to moist surfaces |
US3416530A (en) * | 1966-03-02 | 1968-12-17 | Richard A. Ness | Eyeball medication dispensing tablet |
Cited By (206)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4344431A (en) * | 1969-03-24 | 1982-08-17 | University Of Delaware | Polymeric article for dispensing drugs |
US3993073A (en) * | 1969-04-01 | 1976-11-23 | Alza Corporation | Novel drug delivery device |
US3710796A (en) * | 1971-05-14 | 1973-01-16 | C Neefe | Corneal drug delivery method |
US3960150A (en) * | 1971-09-09 | 1976-06-01 | Alza Corporation | Bioerodible ocular device |
DE2243986A1 (en) * | 1971-09-09 | 1973-03-29 | Alza Corp | BIODEGRADABLE EYE INSERT FOR ADMINISTRATION OF A MEDICINAL PRODUCT |
FR2157798A1 (en) * | 1971-09-09 | 1973-06-08 | Alza Corp | |
US3995635A (en) * | 1971-09-09 | 1976-12-07 | Alza Corporation | Ocular insert |
US3993071A (en) * | 1971-09-09 | 1976-11-23 | Alza Corporation | Bioerodible ocular device |
US3986510A (en) * | 1971-09-09 | 1976-10-19 | Alza Corporation | Bioerodible ocular device |
US3981303A (en) * | 1971-09-09 | 1976-09-21 | Alza Corporation | Bioerodible ocular device |
USB520277I5 (en) * | 1971-09-09 | 1976-02-17 | ||
US3828777A (en) * | 1971-11-08 | 1974-08-13 | Alza Corp | Microporous ocular device |
US3826258A (en) * | 1972-02-07 | 1974-07-30 | S Abraham | Gradual release medicine carrier |
US3870791A (en) * | 1972-04-24 | 1975-03-11 | Heskel M Haddad | Solid state ophthalmic medication delivery method |
US3868445A (en) * | 1972-11-30 | 1975-02-25 | Pharmacia Ab | Dosage unit containing a substance showing a topical effect on the eye, and a method of preparing same |
US3811444A (en) * | 1972-12-27 | 1974-05-21 | Alza Corp | Bioerodible ocular device |
US4177256A (en) * | 1973-04-25 | 1979-12-04 | Alza Corporation | Osmotic bursting drug delivery device |
US3914402A (en) * | 1973-06-14 | 1975-10-21 | Alza Corp | Ophthalmic dosage form, for releasing medication over time |
US3957049A (en) * | 1973-10-09 | 1976-05-18 | Neefe Charles W | Rechargeable drug delivery method |
US3985897A (en) * | 1973-12-21 | 1976-10-12 | Mead Johnson & Company | Ocular hypotensive process employing dextrorotatory sulfonamidophenethanolamines |
US3961628A (en) * | 1974-04-10 | 1976-06-08 | Alza Corporation | Ocular drug dispensing system |
US3926188A (en) * | 1974-11-14 | 1975-12-16 | Alza Corp | Laminated drug dispenser |
US4144317A (en) * | 1975-05-30 | 1979-03-13 | Alza Corporation | Device consisting of copolymer having acetoxy groups for delivering drugs |
US4116241A (en) * | 1976-02-02 | 1978-09-26 | Alza Corporation | Osmotic system with laminated wall comprising structurally different semipermeable lamina |
US4014334A (en) * | 1976-02-02 | 1977-03-29 | Alza Corporation | Laminated osmotic system for dispensing beneficial agent |
US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4190642A (en) * | 1978-04-17 | 1980-02-26 | Alza Corporation | Ocular therapeutic system for dispensing a medication formulation |
US4304226A (en) * | 1980-03-03 | 1981-12-08 | The Procter & Gamble Company | Vaginal contraceptive |
US4281654A (en) * | 1980-04-07 | 1981-08-04 | Alza Corporation | Drug delivery system for controlled ocular therapy |
WO1984004680A1 (en) * | 1983-05-25 | 1984-12-06 | Alcon Lab Inc | Ophthalmic gel |
WO1984004681A1 (en) * | 1983-05-25 | 1984-12-06 | Alcon Lab Inc | Ophthalmic solution |
US4660546A (en) * | 1984-11-07 | 1987-04-28 | Robert S. Herrick | Method for treating for deficiency of tears |
EP0212959A2 (en) * | 1985-08-16 | 1987-03-04 | BAUSCH & LOMB INCORPORATED | Sustained-release formulation containing an amin acid polymer with a lower alkyl (C1-C4) polar solvent |
EP0219208A2 (en) * | 1985-08-16 | 1987-04-22 | BAUSCH & LOMB INCORPORATED | Substained-release formulation containing an amino acid polymer |
EP0212959A3 (en) * | 1985-08-16 | 1988-06-01 | Bausch & Lomb Incorporated | Sustained-release formulation containing an amin acid polymer with a lower alkyl (c1-c4) polar solvent |
EP0219207A3 (en) * | 1985-08-16 | 1988-06-01 | Bausch & Lomb Incorporated | Sustained-release formulation comprising a hydrophobic polymer system |
EP0219208A3 (en) * | 1985-08-16 | 1988-06-01 | Bausch & Lomb Incorporated | Substained-release formulation containing an amino acid polymer |
US4959217A (en) * | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
EP0411578A1 (en) * | 1989-08-01 | 1991-02-06 | Terumo Kabushiki Kaisha | Liquid applicator |
US5054948A (en) * | 1989-08-01 | 1991-10-08 | Terumo Kabushiki Kaisha | Liquid applicator |
US5660851A (en) * | 1989-12-26 | 1997-08-26 | Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem | Ocular inserts |
US5185152A (en) * | 1990-01-10 | 1993-02-09 | Peyman Gholam A | Method and apparatus for controlled release drug delivery to the cornea and anterior chamber of the eye |
US5378475A (en) * | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
WO1993019707A1 (en) * | 1992-04-02 | 1993-10-14 | Bausch & Lomb Incorporated | Ophthalmic article |
EP0863729B1 (en) * | 1995-09-27 | 2004-12-08 | Control Delivery Systems, Inc. | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
EP0863729A1 (en) * | 1995-09-27 | 1998-09-16 | Control Delivery Systems, Inc. | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
US5928662A (en) * | 1996-07-31 | 1999-07-27 | Phillips; Andrew F. | Ocular drug delivery device |
US6123957A (en) * | 1997-07-16 | 2000-09-26 | Jernberg; Gary R. | Delivery of agents and method for regeneration of periodontal tissues |
US5902598A (en) * | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
US6196993B1 (en) | 1998-04-20 | 2001-03-06 | Eyelab Group, Llc | Ophthalmic insert and method for sustained release of medication to the eye |
US20100168073A1 (en) * | 1999-03-22 | 2010-07-01 | Paul Ashton | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
US8252307B2 (en) | 1999-03-22 | 2012-08-28 | Psivida Us, Inc. | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
US20030021828A1 (en) * | 1999-03-22 | 2003-01-30 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with substained release corticosteroids |
WO2000062760A1 (en) | 1999-04-19 | 2000-10-26 | Eyelab Group, Llc | Ophthalmic insert and method for sustained release of medication to the eye |
US20040034357A1 (en) * | 1999-08-03 | 2004-02-19 | University Of Massachusetts, A Massachusetts Corporation | Controlled release implantable devices |
US8574659B2 (en) | 2000-04-26 | 2013-11-05 | Psivida Us, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
US8574613B2 (en) | 2000-04-26 | 2013-11-05 | Psivida Us, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
US6375972B1 (en) | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
US9849085B2 (en) | 2000-04-26 | 2017-12-26 | Psivida Us Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
EP1982701A2 (en) | 2000-04-26 | 2008-10-22 | pSivida Inc | Sustained Release Drug Delivery Devices, Methods of Use, and Methods of Manufacturing Thereof |
US9192579B2 (en) | 2000-04-26 | 2015-11-24 | Psivida Us, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
US6756049B2 (en) | 2000-12-29 | 2004-06-29 | Bausch & Lomb Incorporated | Sustained release drug delivery devices |
US20040208909A1 (en) * | 2000-12-29 | 2004-10-21 | Brubaker Michael J | Sustained release drug delivery devices |
US6756058B2 (en) | 2001-01-03 | 2004-06-29 | Bausch & Lomb Incorporated | Sustained release drug delivery devices with multiple agents |
US20020106395A1 (en) * | 2001-01-03 | 2002-08-08 | Brubaker Michael J. | Sustained release drug delivery devices with prefabricated permeable plugs |
US6964781B2 (en) | 2001-01-03 | 2005-11-15 | Bausch & Lomb Incorporated | Sustained release drug delivery devices with prefabricated permeable plugs |
US6991808B2 (en) | 2001-01-26 | 2006-01-31 | Bausch & Lomb Inc. | Process for the production of sustained release drug delivery devices |
US20060062826A1 (en) * | 2001-01-26 | 2006-03-23 | Brubaker Michael J | Process for the production of sustained release drug delivery devices |
US20020110635A1 (en) * | 2001-01-26 | 2002-08-15 | Brubaker Michael J. | Process for the production of sustained release drug delivery devices |
WO2002064071A1 (en) * | 2001-02-13 | 2002-08-22 | The Lions Eye Institute Of Western Australia | Device and method for anterior segment drug delivery |
US20070026048A1 (en) * | 2001-02-13 | 2007-02-01 | Robert Greenberg | Implantable drug delivery device |
US7181287B2 (en) | 2001-02-13 | 2007-02-20 | Second Sight Medical Products, Inc. | Implantable drug delivery device |
US20020188282A1 (en) * | 2001-02-13 | 2002-12-12 | Robert Greenberg | Implantable drug delivery device |
US7527621B2 (en) | 2001-02-13 | 2009-05-05 | Second Sight Medical Products, Inc. | Implantable drug delivery device |
US20100272777A1 (en) * | 2001-03-15 | 2010-10-28 | The Government Of The United States Of America, As Represented By The Secretary, | Ocular therapeutic agent delivery devices and methdos for making and using such devices |
US20070190111A1 (en) * | 2001-03-15 | 2007-08-16 | Govemment Of The U.S.A, Represented By The Secretary, Department. Of Health And Human | Ocular therapeutic agent delivery devices and methods for making and using such devices |
WO2003096876A2 (en) * | 2001-04-01 | 2003-11-27 | Sommer Phillipe L | Continuously operational diagnostic device |
WO2003096876A3 (en) * | 2001-04-01 | 2004-03-25 | Phillipe L Sommer | Continuously operational diagnostic device |
US7563255B2 (en) | 2001-05-03 | 2009-07-21 | Massachusetts Eye And Ear Infirmary | Implantable drug delivery device and use thereof |
US7404825B2 (en) | 2001-06-11 | 2008-07-29 | Herrick Ii Robert S | Implant capable of forming a differential image in an eye |
US20020198453A1 (en) * | 2001-06-11 | 2002-12-26 | Herrick Family Limited Partnership | Implant capable of forming a differential image in an eye and methods of inserting and locating same |
US20070135914A1 (en) * | 2001-06-11 | 2007-06-14 | Herrick Robert S Ii | Implant capable of forming a differential image in an eye and methods of inserting and locating same |
US20070299515A1 (en) * | 2001-06-11 | 2007-12-27 | Herrick Robert S Ii | Implant capable of forming a differential image in an eye and methods of inserting and locating same |
US10470924B2 (en) | 2001-06-12 | 2019-11-12 | The Johns Hopkins University | Reservoir device for intraocular drug delivery |
US9522082B2 (en) | 2001-06-12 | 2016-12-20 | The Johns Hopkins University | Reservoir device for intraocular drug delivery |
US8486052B2 (en) | 2001-06-12 | 2013-07-16 | The Johns Hopkins University School Of Medicine | Reservoir device for intraocular drug delivery |
US9180046B2 (en) | 2001-06-12 | 2015-11-10 | The Johns Hopkins University School Of Medicine | Reservoir device for intraocular drug delivery |
US20050027312A1 (en) * | 2001-08-10 | 2005-02-03 | Andreas Hahn | Balloon occlusion device |
US8133501B2 (en) | 2002-02-08 | 2012-03-13 | Boston Scientific Scimed, Inc. | Implantable or insertable medical devices for controlled drug delivery |
US8691264B2 (en) | 2002-02-08 | 2014-04-08 | Boston Scientific Scimed, Inc. | Implantable or insertable medical devices for controlled drug delivery |
US8871241B2 (en) | 2002-05-07 | 2014-10-28 | Psivida Us, Inc. | Injectable sustained release delivery devices |
US8685427B2 (en) | 2002-07-31 | 2014-04-01 | Boston Scientific Scimed, Inc. | Controlled drug delivery |
US8920826B2 (en) | 2002-07-31 | 2014-12-30 | Boston Scientific Scimed, Inc. | Medical imaging reference devices |
US9993367B2 (en) | 2003-03-21 | 2018-06-12 | Second Sight Medical Products, Inc. | Transretinal implant and method of manufacture |
US20060270968A1 (en) * | 2003-03-21 | 2006-11-30 | Robert Greenberg | Transretinal implant and method of manufacture |
US20060198892A1 (en) * | 2003-08-22 | 2006-09-07 | Ellis Jeanne Y | Polymeric systems for controlled drug therapy |
US20100178315A1 (en) * | 2003-08-22 | 2010-07-15 | Vista Scientific Llc | Polymeric systems for controlled drug therapy |
US8167855B2 (en) | 2003-08-26 | 2012-05-01 | Vista Scientific Llc | Ocular drug delivery device |
US20070112318A1 (en) * | 2003-08-26 | 2007-05-17 | Leahy Charles D | Ocular drug delivery device |
US8287504B2 (en) | 2003-08-26 | 2012-10-16 | Vista Scientific Llc | Ocular drug delivery device |
US8679078B2 (en) | 2003-08-26 | 2014-03-25 | Vista Scientific Llc | Ocular drug delivery device |
US20100331796A1 (en) * | 2003-08-26 | 2010-12-30 | Vista Scientific Llc | Ocular drug delivery device |
US20060134176A1 (en) * | 2004-12-22 | 2006-06-22 | Bausch & Lomb Incorporated | Pharmaceutical delivery system and method of use |
US20080171072A1 (en) * | 2006-08-11 | 2008-07-17 | Frank Burczynski | Ocular inserts containing apomorphine |
US20080086101A1 (en) * | 2006-08-25 | 2008-04-10 | David Freilich | Ophthalmic insert |
US20090004244A1 (en) * | 2007-06-27 | 2009-01-01 | Orilla Werhner C | Iris design as a drug depot for zonal drug delivery by contact lens |
US20090004245A1 (en) * | 2007-06-28 | 2009-01-01 | Orilla Werhner C | Use of an iris simulated layer to allow aesthetic appearance drug loaded contact lens |
US20090162417A1 (en) * | 2007-12-21 | 2009-06-25 | Cook Incorporated | Drug eluting ocular conformer |
US20100069857A1 (en) * | 2008-09-18 | 2010-03-18 | Oasis Research LLC | Ring Shaped Contoured Collagen Shield For Ophthalmic Drug Delivery |
US7985208B2 (en) * | 2008-09-18 | 2011-07-26 | Oasis Research LLC | Ring shaped contoured collagen shield for ophthalmic drug delivery |
US8414912B2 (en) | 2008-12-11 | 2013-04-09 | Massachusetts Institute Of Technology | Contact lens drug delivery device |
US20100239637A1 (en) * | 2008-12-11 | 2010-09-23 | Massachusetts Institute Of Technology | Contact lens drug delivery device |
US8277830B2 (en) | 2009-01-29 | 2012-10-02 | Forsight Vision4, Inc. | Posterior segment drug delivery |
US9417238B2 (en) | 2009-01-29 | 2016-08-16 | Forsight Vision4, Inc. | Posterior segment drug delivery |
US11642310B2 (en) | 2009-01-29 | 2023-05-09 | Forsight Vision4, Inc. | Posterior segment drug delivery |
US9851351B2 (en) | 2009-01-29 | 2017-12-26 | Forsight Vision4, Inc. | Posterior segment drug delivery |
US10656152B2 (en) | 2009-01-29 | 2020-05-19 | Forsight Vision4, Inc. | Posterior segment drug delivery |
US8795712B2 (en) | 2009-01-29 | 2014-08-05 | Forsight Vision4, Inc. | Posterior segment drug delivery |
US8808727B2 (en) | 2009-01-29 | 2014-08-19 | Forsight Vision4, Inc. | Posterior segment drug delivery |
US8298578B2 (en) | 2009-01-29 | 2012-10-30 | Forsight Vision4, Inc. | Posterior segment drug delivery |
US8399006B2 (en) | 2009-01-29 | 2013-03-19 | Forsight Vision4, Inc. | Posterior segment drug delivery |
US9066779B2 (en) | 2009-01-29 | 2015-06-30 | Forsight Vision4, Inc. | Implantable therapeutic device |
US10813788B2 (en) | 2009-01-29 | 2020-10-27 | Forsight Vision4, Inc. | Implantable therapeutic device |
WO2010093873A2 (en) | 2009-02-12 | 2010-08-19 | Incept, Llc | Drug delivery through hydrogel plugs |
US10004636B2 (en) | 2009-06-03 | 2018-06-26 | Forsight Vision5, Inc. | Anterior segment drug delivery |
US9421126B2 (en) | 2009-06-03 | 2016-08-23 | Forsight Vision5, Inc. | Anterior segment drug delivery |
US10736774B2 (en) | 2009-06-03 | 2020-08-11 | Forsight Vision5, Inc. | Anterior segment drug delivery |
US9005649B2 (en) | 2009-07-14 | 2015-04-14 | Board Of Regents, The University Of Texas System | Methods for making controlled delivery devices having zero order kinetics |
US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
US11077054B2 (en) | 2010-04-03 | 2021-08-03 | Praful Doshi | Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia |
EP3195858A1 (en) | 2010-04-03 | 2017-07-26 | Praful Doshi | Medical devices including medicaments and methods of making and using same |
US10413506B2 (en) | 2010-04-03 | 2019-09-17 | Praful Doshi | Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia |
US10369099B2 (en) | 2010-04-03 | 2019-08-06 | Praful Doshi | Medical devices including medicaments and methods of making and using same |
WO2011123180A1 (en) | 2010-04-03 | 2011-10-06 | Praful Doshi | Medical devices including medicaments and methods of making and using same |
US10842740B2 (en) | 2010-04-03 | 2020-11-24 | Praful Doshi | Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia |
US10188604B2 (en) | 2010-04-03 | 2019-01-29 | Praful Doshi | Medical devices including medicaments and methods of making and using same |
US9931296B2 (en) | 2010-04-03 | 2018-04-03 | Praful Doshi | Medical devices including medicaments and methods of making and using same |
US11234927B2 (en) | 2010-04-03 | 2022-02-01 | Praful Doshi | Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia |
US10076493B2 (en) | 2010-04-03 | 2018-09-18 | Praful Doshi | Medical devices including medicaments and methods of making and using same |
US10632068B2 (en) | 2010-04-03 | 2020-04-28 | Praful Doshi | Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia |
US10045938B2 (en) | 2010-04-03 | 2018-08-14 | Praful Doshi | Medical devices including medicaments and methods of making and using same |
US11510869B2 (en) | 2010-04-03 | 2022-11-29 | Praful Doshi | Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia |
US8765166B2 (en) | 2010-05-17 | 2014-07-01 | Novaer Holdings, Inc. | Drug delivery devices for delivery of ocular therapeutic agents |
US8939948B2 (en) | 2010-06-01 | 2015-01-27 | Forsight Vision5, Inc. | Ocular insert apparatus and methods |
US9937073B2 (en) | 2010-06-01 | 2018-04-10 | Forsight Vision5, Inc. | Ocular insert apparatus and methods |
US9492315B2 (en) | 2010-08-05 | 2016-11-15 | Forsight Vision4, Inc. | Implantable therapeutic device |
US11679027B2 (en) | 2010-08-05 | 2023-06-20 | Forsight Vision4, Inc. | Combined drug delivery methods and apparatus |
US10265215B2 (en) | 2010-08-05 | 2019-04-23 | Forsight Vision4, Inc. | Injector apparatus and method for drug delivery |
US8905963B2 (en) | 2010-08-05 | 2014-12-09 | Forsight Vision4, Inc. | Injector apparatus and method for drug delivery |
US9861521B2 (en) | 2010-08-05 | 2018-01-09 | Forsight Vision4, Inc. | Injector apparatus and method for drug delivery |
US10617557B2 (en) | 2010-08-05 | 2020-04-14 | Forsight Vision4, Inc. | Combined drug delivery methods and apparatus |
US9033911B2 (en) | 2010-08-05 | 2015-05-19 | Forsight Vision4, Inc. | Injector apparatus and method for drug delivery |
US11786396B2 (en) | 2010-08-05 | 2023-10-17 | Forsight Vision4, Inc. | Injector apparatus and method for drug delivery |
WO2012033730A2 (en) | 2010-09-08 | 2012-03-15 | Johnson & Johnson Vision Care, Inc. | Punctal plug containing drug formulation |
US8821457B2 (en) | 2010-09-08 | 2014-09-02 | Johnson & Johnson Vision Care, Inc. | Punctal plug containing drug formulation |
US8894602B2 (en) | 2010-09-17 | 2014-11-25 | Johnson & Johnson Vision Care, Inc. | Punctal plugs with directional release |
WO2012037330A1 (en) | 2010-09-17 | 2012-03-22 | Johnson & Johnson Vision Care, Inc. | Punctal plugs with directional release |
US11065151B2 (en) | 2010-11-19 | 2021-07-20 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
US10874548B2 (en) | 2010-11-19 | 2020-12-29 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
WO2012082486A1 (en) | 2010-12-16 | 2012-06-21 | Johnson & Johnson Vision Care, Inc. | Punctal plug with drug core retention features |
WO2012154427A1 (en) | 2011-05-06 | 2012-11-15 | Johnson & Johnson Vision Care, Inc. | Punctal plugs for controlled release of therapeutic agents |
US9301874B2 (en) | 2011-05-06 | 2016-04-05 | Johnson & Johnson Vision Care, Inc. | Punctal plugs for controlled release of therapeutic agents |
US10398592B2 (en) | 2011-06-28 | 2019-09-03 | Forsight Vision4, Inc. | Diagnostic methods and apparatus |
US11813196B2 (en) | 2011-06-28 | 2023-11-14 | Forsight Vision4, Inc. | Diagnostic methods and apparatus |
US9102105B2 (en) | 2011-09-13 | 2015-08-11 | Vista Scientific Llc | Method for forming an ocular drug delivery device |
US10835416B2 (en) | 2011-09-14 | 2020-11-17 | Forsight Vision5, Inc. | Ocular insert apparatus and methods |
US8715712B2 (en) | 2011-09-14 | 2014-05-06 | Forsight Vision5, Inc. | Ocular insert apparatus and methods |
US9883968B2 (en) | 2011-09-16 | 2018-02-06 | Forsight Vision4, Inc. | Fluid exchange apparatus and methods |
US10653554B2 (en) | 2011-09-16 | 2020-05-19 | Forsight Vision4, Inc. | Fluid exchange apparatus and methods |
US10603209B2 (en) | 2012-02-03 | 2020-03-31 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
US10010448B2 (en) | 2012-02-03 | 2018-07-03 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
EP2633840A2 (en) | 2012-02-29 | 2013-09-04 | Johnson & Johnson Vision Care, Inc. | Punctal plug with energized containment array |
US10456293B2 (en) | 2012-10-26 | 2019-10-29 | Forsight Vision5, Inc. | Ophthalmic system for sustained release of drug to eye |
US9750636B2 (en) | 2012-10-26 | 2017-09-05 | Forsight Vision5, Inc. | Ophthalmic system for sustained release of drug to eye |
US9968603B2 (en) | 2013-03-14 | 2018-05-15 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
US9526654B2 (en) | 2013-03-28 | 2016-12-27 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
US10398593B2 (en) | 2013-03-28 | 2019-09-03 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
US11510810B2 (en) | 2013-03-28 | 2022-11-29 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
US10098836B2 (en) | 2013-05-02 | 2018-10-16 | Retina Foundation Of The Southwest | Method for forming a molded two-layer ocular implant |
US10449145B2 (en) | 2013-05-02 | 2019-10-22 | Retina Foundation Of The Southwest | Two-layer ocular implant |
US10881609B2 (en) | 2013-05-02 | 2021-01-05 | Retina Foundation Of The Southwest | Methods for treating eye disorders using ocular implants |
WO2015071427A1 (en) | 2013-11-14 | 2015-05-21 | Eyed Pharma | Eye device |
EP3566693A1 (en) | 2013-11-14 | 2019-11-13 | EyeD Pharma | Eye device |
WO2015164563A1 (en) | 2014-04-25 | 2015-10-29 | Johnson & Johnson Vision Care, Inc. | Method and ophthalmic device with active agent release system |
US10258503B2 (en) | 2014-07-15 | 2019-04-16 | Forsight Vision4, Inc. | Ocular implant delivery device and method |
US11337853B2 (en) | 2014-07-15 | 2022-05-24 | Forsight Vision4, Inc. | Ocular implant delivery device and method |
US10363255B2 (en) | 2014-08-08 | 2019-07-30 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
US9895369B2 (en) | 2014-08-08 | 2018-02-20 | Forsight Vision4, Inc | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
US9474756B2 (en) | 2014-08-08 | 2016-10-25 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
US10765677B2 (en) | 2014-08-08 | 2020-09-08 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
US11617644B2 (en) | 2014-10-13 | 2023-04-04 | W. L. Gore & Associates, Inc. | Prosthetic valved conduit |
US10500091B2 (en) | 2014-11-10 | 2019-12-10 | Forsight Vision4, Inc. | Expandable drug delivery devices and methods of use |
US11110001B2 (en) | 2014-11-10 | 2021-09-07 | Forsight Vision4, Inc. | Expandable drug delivery devices and methods of use |
US11224602B2 (en) | 2015-04-13 | 2022-01-18 | Forsight Vision5, Inc. | Ocular insert composition of a semi-crystalline or crystalline pharmaceutically active agent |
US10010502B2 (en) | 2015-05-19 | 2018-07-03 | Amorphex Therapeutics Llc | Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation |
US10172740B2 (en) | 2015-11-06 | 2019-01-08 | David E Freilich | Lacrimal stent |
US11432959B2 (en) | 2015-11-20 | 2022-09-06 | Forsight Vision4, Inc. | Porous structures for extended release drug delivery devices |
US11617680B2 (en) | 2016-04-05 | 2023-04-04 | Forsight Vision4, Inc. | Implantable ocular drug delivery devices |
WO2018119188A2 (en) | 2016-12-21 | 2018-06-28 | Johnson & Johnson Vision Care, Inc. | Extended period timer circuits for ophthalmic devices |
US11351058B2 (en) | 2017-03-17 | 2022-06-07 | W. L. Gore & Associates, Inc. | Glaucoma treatment systems and methods |
US11523940B2 (en) | 2017-03-17 | 2022-12-13 | W. L. Gore & Associates, Inc. | Delivery aids for glaucoma shunts |
US11406533B2 (en) | 2017-03-17 | 2022-08-09 | W. L. Gore & Associates, Inc. | Integrated aqueous shunt for glaucoma treatment |
US11419759B2 (en) | 2017-11-21 | 2022-08-23 | Forsight Vision4, Inc. | Fluid exchange apparatus for expandable port delivery system and methods of use |
US11678983B2 (en) | 2018-12-12 | 2023-06-20 | W. L. Gore & Associates, Inc. | Implantable component with socket |
USD1033637S1 (en) | 2022-01-24 | 2024-07-02 | Forsight Vision4, Inc. | Fluid exchange device |
Also Published As
Publication number | Publication date |
---|---|
BE771356A (en) | 1971-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3618604A (en) | Ocular insert | |
US3630200A (en) | Ocular insert | |
US3626940A (en) | Ocular insert | |
US3828777A (en) | Microporous ocular device | |
US3995635A (en) | Ocular insert | |
US3845201A (en) | Solid state ophthalmic medication delivery method | |
US3854480A (en) | Drug-delivery system | |
US4484922A (en) | Occular device | |
US3867519A (en) | Bioerodible drug delivery device | |
US4882150A (en) | Drug delivery system | |
US4865846A (en) | Drug delivery system | |
US3870791A (en) | Solid state ophthalmic medication delivery method | |
US3786812A (en) | Contact lens for olar drug delivery | |
US3962414A (en) | Structured bioerodible drug delivery device | |
CA2165071C (en) | Ocular insert with anchoring protrusions | |
US4923699A (en) | Eye treatment suspension | |
US6264971B1 (en) | Ocular insert | |
US3811444A (en) | Bioerodible ocular device | |
US5989579A (en) | Ocular insert with anchoring protrusions | |
US5147647A (en) | Ocular insert for the fornix | |
US3914402A (en) | Ophthalmic dosage form, for releasing medication over time | |
US5472436A (en) | Ocular appliance for delivering medication | |
US3986510A (en) | Bioerodible ocular device | |
US3625214A (en) | Drug-delivery device | |
US3826258A (en) | Gradual release medicine carrier |